What does BioPharma Management and Consulting do?

BioPharma Management and Consulting is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”. Also registered: property company, training centre. Private Limited, started on 17 October 2016, 1 establishment.

What is the address of BioPharma Management and Consulting?

The registered office of BioPharma Management and Consulting is located at Viscourt(Cle) 2, 5650 Walcourt.

Is BioPharma Management and Consulting still active?

Yes. According to the CBE (17 September 2026) BioPharma Management and Consulting is active, legal situation “Normale toestand”, started on 17 October 2016.

Is BioPharma Management and Consulting registered on Peppol?

Yes, BioPharma Management and Consulting is registered on the Peppol network with ID 0208:0664691906.

What is the enterprise number of BioPharma Management and Consulting?

The enterprise number of BioPharma Management and Consulting is BE0664691906.

When was BioPharma Management and Consulting founded?

BioPharma Management and Consulting was founded on 17 October 2016.

Who are the directors of BioPharma Management and Consulting?

According to the 2025 annual accounts, the directors of BioPharma Management and Consulting are: Denis Bedoret.

Is BioPharma Management and Consulting a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 October 2016; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did BioPharma Management and Consulting make in 2025?

BioPharma Management and Consulting posted a profit after taxes of € 29,020 in financial year 2025.

What is the revenue of BioPharma Management and Consulting?

As a small company, BioPharma Management and Consulting is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 191,251.

BioPharma Management and Consulting (Private Limited)

Dossier BioPharma Management and Consulting, printed on 17 September 2026 from databakkes.be/en/0664691906/biopharma-management-and-consulting. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BioPharma Management and Consulting from Walcourt, company number BE0664691906, closed financial year 2025 with a result of € 29,020 after tax. For that financial year BioPharma Management and Consulting recorded a gross margin of € 191,251 and equity of € 18,600. Compared with financial year 2024, the result moved from € 58,009 to € 29,020. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Healthy

€ 18,600

▼ 44% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 29,020

▼ 50% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 132,455

▲ 54% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 43,888 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 2.9 million

▼ 4% vs 2024

Of which on lease € 2.9 million.

Debts at end 2025

Bank debt ≈ 26 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3 million

▼ 4% vs 2024

€ 112,872 is repaid this year. At this pace the long-term loan is gone in ≈ 26 years.

Owed to suppliers

€ 10,159

▲ 65% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 14,948

▲ 72% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 340,487 Gross margin 2022: € 340,487 First fiscal year in the series	€ 309,080 Gross margin 2023: € 309,080 ▼ 9% vs 2022 (€ 340,487) Unfavourable step	€ 229,502 Gross margin 2024: € 229,502 ▼ 26% vs 2023 (€ 309,080) Unfavourable step	€ 191,251 Gross margin 2025: € 191,251 ▼ 17% vs 2024 (€ 229,502) Unfavourable step	▼ 17%
Profit after taxes	€ 255,596 Profit after taxes 2022: € 255,596 First fiscal year in the series	€ 211,027 Profit after taxes 2023: € 211,027 ▼ 17% vs 2022 (€ 255,596) Unfavourable step	€ 58,009 Profit after taxes 2024: € 58,009 ▼ 73% vs 2023 (€ 211,027) Unfavourable step	€ 29,020 Profit after taxes 2025: € 29,020 ▼ 50% vs 2024 (€ 58,009) Unfavourable step	▼ 50%
Equity	€ 20,460 Equity 2022: € 20,460 First fiscal year in the series	€ 20,460 Equity 2023: € 20,460 Unchanged (€ 20,460) Unchanged	€ 33,469 Equity 2024: € 33,469 ▲ 64% vs 2023 (€ 20,460) Favourable step	€ 18,600 Equity 2025: € 18,600 ▼ 44% vs 2024 (€ 33,469) Unfavourable step	▼ 44%
Total debts	€ 289,996 Total debts 2022: € 289,996 First fiscal year in the series	€ 3,333,558 Total debts 2023: € 3,333,558 ▲ € 3 million vs 2022 (€ 289,996) Unfavourable step	€ 3,236,435 Total debts 2024: € 3,236,435 ▼ 3% vs 2023 (€ 3,333,558) Favourable step	€ 3,141,610 Total debts 2025: € 3,141,610 ▼ 3% vs 2024 (€ 3,236,435) Favourable step	▼ 3%
Cash	€ 253,667 Cash 2022: € 253,667 First fiscal year in the series	€ 105,500 Cash 2023: € 105,500 ▼ 58% vs 2022 (€ 253,667) Unfavourable step	€ 85,839 Cash 2024: € 85,839 ▼ 19% vs 2023 (€ 105,500) Unfavourable step	€ 132,455 Cash 2025: € 132,455 ▲ 54% vs 2024 (€ 85,839) Favourable step	▲ 54%
Land & buildings	-	€ 29,360 Land & buildings 2023: € 29,360 First fiscal year in the series	€ 28,672 Land & buildings 2024: € 28,672 ▼ 2% vs 2023 (€ 29,360) Unchanged	€ 27,816 Land & buildings 2025: € 27,816 ▼ 3% vs 2024 (€ 28,672) Unchanged	▼ 3%
Retained profit	€ 1,860 Retained profit 2022: € 1,860 First fiscal year in the series	€ 1,860 Retained profit 2023: € 1,860 Unchanged (€ 1,860) Unchanged	€ 14,869 Retained profit 2024: € 14,869 ▲ € 13,009 vs 2023 (€ 1,860) Favourable step	€ 0 Retained profit 2025: € 0 ▼ 100% vs 2024 (€ 14,869) Unfavourable step	▼ 100%
Dividend	€ 255,596 Dividend 2022: € 255,596 First fiscal year in the series	€ 211,027 Dividend 2023: € 211,027 ▼ 17% vs 2022 (€ 255,596) Unchanged	€ 45,000 Dividend 2024: € 45,000 ▼ 79% vs 2023 (€ 211,027) Unchanged	€ 43,888 Dividend 2025: € 43,888 ▼ 2% vs 2024 (€ 45,000) Unchanged	▼ 2%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 3,096,894 Bank debt 2023: € 3,096,894 Unchanged (€ 0) Unfavourable step	€ 3,073,653 Bank debt 2024: € 3,073,653 ▼ 1% vs 2023 (€ 3,096,894) Favourable step	€ 2,957,307 Bank debt 2025: € 2,957,307 ▼ 4% vs 2024 (€ 3,073,653) Favourable step	▼ 4%
Balance sheet total	€ 310,456 Balance sheet total 2022: € 310,456 First fiscal year in the series	€ 3,354,018 Balance sheet total 2023: € 3,354,018 ▲ € 3 million vs 2022 (€ 310,456) Unchanged	€ 3,269,904 Balance sheet total 2024: € 3,269,904 ▼ 3% vs 2023 (€ 3,354,018) Unchanged	€ 3,160,210 Balance sheet total 2025: € 3,160,210 ▼ 3% vs 2024 (€ 3,269,904) Unchanged	▼ 3%

Key figures of BioPharma Management and Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BioPharma Management and Consulting?

What happened at BioPharma Management and Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2026 New annual accounts for financial year 2025: profit of € 29,020 (▼ 50% vs 2024). Source: NBB ↗
Oct 17, 2016 New establishment in Walcourt. KBO
Oct 17, 2016 Start of the company according to the CBE. KBO

In short

From € 255,596 profit in 2022 to € 29,020 profit in 2025.

Paid € 168,660 in corporate taxes since 2022.

Best year ever: 2022, with € 255,596 profit.

Paid out € 555,512 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at BioPharma Management and Consulting? We notify you, reason included.

Follow BioPharma Management and Consulting

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Denis Bedoret

BioPharma Management and Consulting

NEUVASQ BIOTECHNOLOGIES

IMCYSE

Behind BioPharma Management and Consulting is Denis Bedoret. Denis Bedoret is also behind NEUVASQ BIOTECHNOLOGIES and IMCYSE.

See the full network in the app

Directors

According to the 2025 annual accounts

Denis Bedoret

Administrator-manager

Also active at: NEUVASQ BIOTECHNOLOGIES, IMCYSE

Establishments

Establishment units

Physical locations of this company

Registered office

Viscourt(Cle) 2

5650 Walcourt

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0664.691.906

VAT number

BE 0664.691.906

Registered office

Viscourt(Cle) 2, 5650 Walcourt

Names & denominations

BioPharma Management and Consulting · BM&C

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

17 October 2016

Peppol

Active · Active since 10 Aug 2026

Contact

[email protected]

Activities · NACE

Overige zakelijke dienstverlening, neg

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

Overige vormen van onderwijs

View on CBE Public ↗ Annual accounts (NBB) ↗